ADC Therapeutics SA (ADCT) is a leading oncology-focused biotechnology company that specializes in the development and commercialization of highly potent and targeted antibody-drug conjugates (ADCs) for patients battling hematologic cancers and solid tumors. The firm's ADCs are a class of medications designed to harness the targeting ability of monoclonal antibodies by linking them to cell-killing agents.
The company's headquarters are in Switzerland, but it has additional offices in London, San Francisco, New Jersey, and New York, enabling it to carry out operations and research globally. Notably, ADC Therapeutics has a state-of-the-art laboratory in London where it carries out its research activities.
ADCT has established a strong portfolio in the pharmaceutical market. Its lead product, Lonca (loncastuximab tesirine), received accelerated approval from the U.S. Food and Drug Administration (FDA) in April 2021 for treatment of relapsed or refractory diffuse large B-cell lymphoma, a type of non-Hodgkin lymphoma.
ADC Therapeutics is continuously working on advancing its pipeline of proprietary ADCs with multiple ongoing clinical trials. Another one of its product candidates, Cami (camidanlumab tesirine) has demonstrated antitumor activity in a pivotal Phase 2 clinical trial for patients with relapsed or refractory Hodgkin lymphoma and is nearing potential commercialization.
Apart from Lonca and Cami, the company has multiple other ADCs in advanced clinical development which target different types of cancers. The company's pipeline demonstrates its commitment to revolutionize cancer treatment.
Innovation is core to the company's strategy, as it continues to develop advanced ADCs that can cater to various hematologic cancers and solid tumors. ADC Therapeutics thrives on a diverse, multinational workforce who shares their expertise and dedication toward the common goal of improving patients’ lives.
ADC Therapeutics SA (ADCT) is a publicly traded company, with its shares listed on the New York Stock Exchange. With a market cap in the billions, the company's work and future potential are recognized and backed by substantial investors worldwide.
Through its innovative drugs and dedication to cancer treatment, ADC Therapeutics is poised to make a significant global impact in oncology. Their vision is to leverage the full power of ADCs and become the leading developer in this vital sector of pharmaceutical research and development.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
ADC Therapeutics SA reported a loss per share of $0.06 for Q3 2026, with a net loss of $8.8 million, demonstrating ongoing investment in its antibody drug conjugate platform. Despite the loss, the company generated $21.7 million in revenue, a 32.1% increase from Q3 2025, indicating growing commercial traction for its targeted cancer treatments. Wall Street analysts maintain a generally positive outlook, with 4 buy and 3 hold ratings.
ADC Therapeutics SA (ADCT) has published a slide deck detailing its ZYNLONTA data presented at ASH and its strategic financial restructuring efforts. The company's presentation provides insights into its recent developments and future plans regarding its key therapeutic asset. This information is available for investors and interested parties to review.
AIGH Capital Management LLC has purchased a new stake of 4.32 million shares in ADC Therapeutics SA (NYSE:ADCT), valued at approximately $5.28 million, representing 3.39% of the company. Other institutional investors also adjusted their holdings. ADC Therapeutics recently reported a quarterly EPS loss of $0.11, beating analysts' estimates, and revenue of $19.25 million, also exceeding expectations, though shares were reported down 4.9%.
ADC Therapeutics SA (NYSE:ADCT) announced the grant of options to purchase 17,000 common shares to a new employee on November 2, 2026. This grant serves as a material inducement for employment and was approved under the company's Inducement Plan and NYSE Listed Company Manual Rule 303A.08. The options have a four-year vesting schedule, with 25% vesting on the first anniversary and the remainder vesting monthly thereafter, contingent on continued employment.
ADC Therapeutics faces a critical moment as it heads into its third-quarter report, needing to demonstrate that its Lotus 7 strategy can succeed after its Lotus 5 growth driver encountered FDA regulatory issues. The company must provide clear updates on Lotus 7's regulatory path and show evidence of cost savings to maintain investor confidence following a significant stock rebound from a previous low. The market is looking for concrete plans to replace lost catalysts and validate its pivot.